Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PYXSBearishIndustry Newsnews

High materiality7/10

Pyxis MICVO shows solid efficacy but safety concerns weigh near-term risk

Sep 9, 2026, 2:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The stock fell ~9% after mixed Phase 1 results despite strong efficacy signals, due to safety liabilities and uncertainty around Phase 3 timing and regulatory decisions.

AI summary

What happened, with direct paths to the underlying reporting

Pyxis Oncology reported MICVO Phase 1 data in head and neck cancer showing 36% objective response rate, 94% disease control rate, and a 6.2-month median progression-free survival at 5.4 mg/kg. While 12-month overall survival probability reached 79% with no new safety signals among evaluable patients, 54% experienced grade 3+ adverse events and 14% discontinued, underscoring safety liability ahead of a mid-2027 Phase 3 readout and FDA dose discussions.

MICVO Phase 1 in head and neck cancer: 33 evaluable; 36% ORR, 94% DCR at 5.4 mg/kg.
PFS 6.2 months; 12-month OS probability 79%; no new safety signals in 35 evaluable.
FDA meeting planned for Q1 2027 to finalize dose via Project Optimus; Phase 3 mid-2027.
Phase 1/2 data for MICVO+KEYTRUDA expected Q4 2026; durability metrics by late 2027.
Pyxis stock trades down ~9.25% on data; safety liabilities remain a concern.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.